Detalles de la búsqueda
1.
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
Breast Cancer Res Treat
; 188(1): 117-131, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33763789
2.
The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.
Breast Cancer Res Treat
; 185(1): 125-134, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32920732
3.
TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study.
Invest New Drugs
; 38(1): 140-147, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31289984
4.
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.
Br J Cancer
; 120(5): 475-480, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30745582
5.
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.
Breast Cancer
; 2024 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38642245
6.
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.
Breast Cancer
; 30(6): 872-884, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37804479
7.
Deregulation of protein phosphatase 2A inhibitor SET is associated with malignant progression in breast cancer.
Sci Rep
; 11(1): 14238, 2021 07 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34244560
8.
Dose-dense adjuvant chemotherapy: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2018 edition.
Breast Cancer
; 27(3): 334-339, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31916188
9.
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.
Breast Cancer
; 27(3): 322-331, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32240526
10.
[Prognostic significance of the number of axillary lymph nodes examined in breast cancer].
Nihon Rinsho
; 70 Suppl 7: 154-7, 2012 Sep.
Artículo
en Japonés
| MEDLINE | ID: mdl-23350383
11.
A Real-World Retrospective Cohort Study of Combined Therapy with Bevacizumab and Paclitaxel in Japanese Patients with Metastatic Breast Cancer.
J Nippon Med Sch
; 84(5): 215-223, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29142182
12.
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.
Clin Breast Cancer
; 17(8): 585-594.e4, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28830796
13.
Correction to: The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.
Breast Cancer
; 28(4): 985-986, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33886078
14.
Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer.
Oncol Lett
; 5(1): 83-89, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23255899
Resultados
1 -
14
de 14
1
Próxima >
>>